Shanghai Caerulum Pharma Discovery

CYC065 is an orally bioavailable inhibitor of cyclin dependent kinases 2, 5 and 9 (CDK2/5/9) with potential antineoplastic and chemoprotective activities. CYC065 selectively binds to and inhibits the activity of CDK2, 5 and 9, which leads to inhibition of CDK2, 5 and 9-dependent cellular pathways, downregulation of genes involved in the pro-survival pathway, prevention of the activation of DNA double-strand break repair pathways, and induction of both cell cycle arrest and apoptosis. This inhibits the proliferation of CDK2/5/9-overexpressing tumor cells. In addition, CYC065 protects hematopoietic stem and progenitor cells (HSPCs), prevents myelosuppression, and preserves the function of the bone marrow.

Shanghai Caerulum Pharma Discovery is the manufacturer of APIs and intermediates of some of the latest compounds in the market. Our focus is on cancer, diabetes and other therapeutic areas.

Shanghai Caerulum Pharma Discovery (CPD) offers high quality and reliable chemical products and integrated biological services including:

1)       Best offer for existing APIs and intermediates

2)       Custom-synthesis APIs and intermediates

3)       DMPK

4)       Biological screening

5)       Drug Safety Evaluation